Date of Award


Document Type


Degree Name

Medical Doctor (MD)



First Advisor

Shari Damast



Purpose: Little data exists to guide the appropriate use of invasive mediastinal staging in patients with clinically node-negative NSCLC staged by PET-CT. We examined a large cohort of patients with clinical stage I NSCLC determined by PET-CT to determine which patients benefit from invasive staging.

Materials/Methods: We identified consecutive clinical T1-2N0 NSCLC patients being evaluated for curative-intent therapy between 2011 and 2015. None had evidence of nodal disease by PET-CT; the endpoint was pathologic confirmation of occult N2 disease. Tumor size, location, histology, SUVmax, and radiographic appearance were evaluated as determinants of occult N2 disease. Two group comparisons of continuous variables were done with independent t-tests and categorical variables were compared with or Fisher’s exact test.

Results: In 284 patients with PET-CT-staged clinical T1-2N0 disease, the prevalence of occult N2 metastases was 7.0%. The negative predictive value of PET-CT was 92.9% and the negative predictive value of mediastinoscopy/EBUS was 96.3%.

T2 tumors were more likely to have occult N2 disease than T1 tumors (11.8% v 3.6% p=0.009). Pure solid tumors had greater involvement of N2 nodes than tumors with any ground glass component (12.6% v 1.5%, p=0.001). 17.5% of central tumor cases were found to have occult N2 metastases while 4.4% of patients with peripheral tumors (P

Conclusions: Invasive mediastinal staging should be strongly encouraged in central tumors and solid T2 tumors because the risk of occult nodal involvement is greater than 10% in these cohorts. However, for patients with peripheral T1 tumors, the yield of invasive staging after a negative PET-CT is very low and invasive staging may not be warranted.


This thesis is restricted to Yale network users only.